## Statin Drugs and Risk of Advanced Prostate Cancer

Journal of the National Cancer Institute 98, 1819-1825 DOI: 10.1093/jnci/djj499

**Citation Report** 

#	Article	IF	CITATIONS
1	Analysis of the National Health and Nutrition Examination Survey. Survey of Ophthalmology, 2006, 51, 525-526.	4.0	2
2	Do Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1587-1594.	2.5	59
3	Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications. Current Pharmaceutical Design, 2007, 13, 3622-3636.	1.9	87
4	Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2226-2232.	2.5	166
5	Cholesterol-Lowering Drugs and Advanced Prostate Cancer Incidence in a Large U.S. Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2213-2217.	2.5	136
6	Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2175-2180.	2.5	19
7	Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2218-2225.	2.5	134
8	Cholesterol Sensitivity of Endogenous and Myristoylated Akt. Cancer Research, 2007, 67, 6238-6246.	0.9	114
10	Prostate cancer prevention. Cancer, 2007, 110, 1889-1899.	4.1	60
11	Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer, 2007, 110, 2119-2152.	4.1	497
12	Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFRâ€mediated Akt and ERK signal transduction. Prostate, 2007, 67, 1061-1069.	2.3	90
13	Obesity and Prostate Cancer: A Role for Adipokines. European Urology, 2007, 52, 46-53.	1.9	137
15	Dietary fat'gene interactions in cancer. Cancer and Metastasis Reviews, 2007, 26, 535-551.	5.9	52
16	Statin use and prostate cancer risk in a large population-based setting. Cancer Causes and Control, 2008, 19, 767-774.	1.8	63
17	Hypercholesterolemia and prostate cancer: a hospital-based case–control study. Cancer Causes and Control, 2008, 19, 1259-1266.	1.8	80
18	Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction. Journal of Bioenergetics and Biomembranes, 2008, 40, 307-314.	2.3	36
19	Rationale for statins in the chemoprevention of prostate cancer. Current Prostate Reports, 2008, 6, 99-106.	0.1	1
20	Rationale for statins in the chemoprevention of prostate cancer. Current Urology Reports, 2008, 9, 189-196.	2.2	23

#	Article	IF	CITATIONS
21	Pharmacokinetics, Pharmacodynamics and Drug Metabolism. Journal of Pharmaceutical Sciences, 2008, 97, 4528-4545.	3.3	35
22	Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. International Journal of Cancer, 2008, 123, 899-904.	5.1	134
23	Association between plasma cholesterol and prostate cancer in the PSA era. International Journal of Cancer, 2008, 123, 1693-1698.	5.1	117
24	Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention. International Journal of Cancer, 2008, 123, 983-990.	5.1	83
25	New pharmacological strategies against metastatic spread. Fundamental and Clinical Pharmacology, 2008, 22, 465-492.	1.9	19
26	Impact of statin therapy on survival in epithelial ovarian cancer. Gynecologic Oncology, 2008, 111, 102-105.	1.4	72
27	Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochemical Pharmacology, 2008, 75, 907-913.	4.4	108
28	Progress in Understanding Androgen-Independent Prostate Cancer (AIPC): A Review of Potential Endocrine-Mediated Mechanisms. European Urology, 2008, 53, 1129-1137.	1.9	65
29	Statins and Cancer Risk. American Journal of Medicine, 2008, 121, 302-309.	1.5	125
30	Consumption of dietary supplements and over-the-counter and prescription medications in men participating in the Prostate Cancer Prevention Trial at an academic center. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 125-132.	1.6	19
31	Exploring causes for declining prostate cancer mortality rates in the United States. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 627-633.	1.6	17
32	Do the cholesterol-lowering properties of statins affect cancer risk?. Trends in Endocrinology and Metabolism, 2008, 19, 113-121.	7.1	109
33	Statins in tumor suppression. Cancer Letters, 2008, 260, 11-19.	7.2	156
34	Statins and cancer: A systematic review and meta-analysis. European Journal of Cancer, 2008, 44, 2122-2132.	2.8	257
35	Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells. Biochemical and Biophysical Research Communications, 2008, 365, 131-136.	2.1	24
36	Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochemical and Biophysical Research Communications, 2008, 372, 356-361.	2.1	49
37	Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase. Cell Cycle, 2008, 7, 2257-2267.	2.6	80
38	Statins and prostate cancer prevention: where we are now, and future directions. Nature Reviews Urology, 2008, 5, 376-387.	1.4	62

#	Article	IF	CITATIONS
39	The Influence of Statin Medications on Prostate-specific Antigen Levels. Journal of the National Cancer Institute, 2008, 100, 1511-1518.	6.3	145
40	Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study. American Journal of Epidemiology, 2008, 168, 250-260.	3.4	143
41	Chinese Red Yeast Rice Versus Lovastatin Effects on Prostate Cancer Cells With and Without Androgen Receptor Overexpression. Journal of Medicinal Food, 2008, 11, 657-666.	1.5	34
42	Prevention of Prostate Cancer: What We Know and Where We Are Going. American Journal of Men's Health, 2008, 2, 178-189.	1.6	7
43	Review of recent evidence in support of a role for statins in the prevention of prostate cancer. Current Opinion in Urology, 2008, 18, 333-339.	1.8	35
45	Prostate cancer update: 2007. Current Opinion in Oncology, 2008, 20, 294-299.	2.4	6
47	Androgens and prevention of prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 271-277.	2.3	3
48	Cholesterol and Cholesterol-Rich Membranes in Prostate Cancer: An Update. Tumori, 2008, 94, 633-639.	1.1	60
49	Lack of Efficacy of the Statins Atorvastatin and Lovastatin in Rodent Mammary Carcinogenesis. Cancer Prevention Research, 2009, 2, 161-167.	1.5	33
50	A 64-Year-Old Man With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2009, 301, 2141.	7.4	18
51	Does statin use affect the risk of developing prostate cancer?. Nature Reviews Urology, 2009, 6, 70-71.	1.4	6
52	Prostate-Cancer Screening. New England Journal of Medicine, 2009, 361, 202-206.	27.0	15
53	Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochemical Pharmacology, 2009, 78, 1115-1126.	4.4	62
54	Pharmacological Approaches to Reducing the Risk of Prostate Cancer. European Urology, 2009, 55, 1064-1074.	1.9	25
55	Editorial Comment on: Pharmacological Approaches to Reducing the Risk of Prostate Cancer. European Urology, 2009, 55, 1073-1074.	1.9	0
56	Chemoprevention of prostate cancer: What can be recommended to patients?. Current Prostate Reports, 2009, 7, 47-53.	0.1	0
57	Chemoprevention of prostate cancer: What can be recommended to patients?. Current Urology Reports, 2009, 10, 165-171.	2.2	28
58	Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial Cells at therapeutic concentrations. Prostate, 2009, 69, 1017-1023.	2.3	43

#	Article	IF	CITATIONS
59	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics, 2009, 2, 2.	1.5	421
60	Metabolic Syndrome and Prostate Cancer: A Review. Clinical Oncology, 2009, 21, 183-191.	1.4	27
61	Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Current Opinion in Pharmacology, 2009, 9, 419-426.	3.5	64
62	No Effect of Statins on Biochemical Outcomes After Radiotherapy for Localized Prostate Cancer. Urology, 2009, 73, 158-162.	1.0	55
63	High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 170-173.	1.6	14
64	Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 126-136.	2.5	49
65	Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2807-2813.	2.5	150
66	Ezetimibe Is an Inhibitor of Tumor Angiogenesis. American Journal of Pathology, 2009, 174, 1017-1026.	3.8	100
67	The Influence of Statin Medications on Prostate-specific Antigen Levels. Yearbook of Urology, 2009, 2009, 2009, 158-159.	0.1	0
68	ASSOCIATION BETWEEN STATINS, OBESITY AND PROSTATE TUMOR INFLAMMATORY INFILTRATE IN MEN UNDERGOING RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 205-205.	0.4	Ο
69	Risk Factors, Prevention and Early Detection of Prostate Cancer. Primary Care - Clinics in Office Practice, 2009, 36, 603-621.	1.6	6
70	Dietary intervention strategies to modulate prostate cancer risk and prognosis. Current Opinion in Urology, 2009, 19, 263-267.	1.8	25
71	Statins and Cancer: A Potential Link?. American Journal of Therapeutics, 2010, 17, e100-e104.	0.9	2
72	Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes and Control, 2010, 21, 61-68.	1.8	91
73	Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001–2004. Cancer Causes and Control, 2010, 21, 671-678.	1.8	39
74	Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. Cancer Causes and Control, 2010, 21, 1575-1583.	1.8	20
75	A Clinical Review of Statins and Cancer: Helpful or Harmful?. Pharmacotherapy, 2010, 30, 177-194.	2.6	29
76	Re: Effects of Simvastatin, Acetylsalicylic Acid, and Rosiglitazone on Proliferation of Normal and Cancerous Prostate Epithelial Cells at Therapeutic Concentrations. European Urology, 2010, 57, 542-543.	1.9	0

ARTICLE IF CITATIONS # Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian 1.4 48 77 cancers. Gynecológic Oncology, 2010, 116, 78-81. Statin medication use and the risk of biochemical recurrence after radical prostatectomy. Cancer, 4.1 2010, 116, 3389-3398. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castrationâ€resistant prostate cancer in a mouse xenograft model. Prostate, 79 2.3 142 2010, 70, 390-400. The impact of HMGâ€CoA reductase therapy on serum PSA. Prostate, 2010, 70, 608-615. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate, 2010, 70, 883-888. 81 2.3 22 Statinâ€induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells. Prostate, 2010, 70, 971-981. 2.3 104 Statin and NSAID use and prostate cancer risk. Pharmacoepidemiology and Drug Safety, 2010, 19, 752-755. 83 1.9 29 The Rafts of the Medusa: cholesterol targeting in cancer therapy. Oncogene, 2010, 29, 3745-3747. 84 19 85 Is statin use associated with prostate cancer aggressiveness?. BJU International, 2010, 105, 1222-1225. 2.5 36 Association of statin and nonsteroidal antiâ€inflammatory drug use with prostate cancer outcomes: 2.5 38 results from CaPSURE. BJU International, 2010, 106, 627-632. Metabolomic Characterization of Human Prostate Cancer Bone Metastases Reveals Increased Levels of 87 135 2.5 Cholesterol. PLoS ONE, 2010, 5, e14175. Prevention Strategies in Prostate Cancer. Current Oncology, 2010, 17, 4-10. 2.2 Methyl-Î<sup>2</sup>-cyclodextrin Suppresses Hyaluronan Synthesis by Down-regulation of Hyaluronan Synthase 2 89 3.4 33 through Inhibition of Akt. Journal of Biological Chemistry, 2010, 285, 22901-22910. Association between Statins and Prostate Tumor Inflammatory Infiltrate in Men Undergoing Radical 2.5 Prostatectomy. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 722-728. Statin Use and the Risk of Prostate-Specific Antigen Recurrence After Radiation Therapy With or 91 1.6 9 Without Hormone Therapy for Prostate Cancer. Journal of Clinical Oncology, 2010, 28, 2651-2652. Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. Journal of 146 Clinical Oncology, 2010, 28, 2653-2659. Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP 93 1.568 Xenograft Prostate Tumors to Androgen Independence. Cancer Prevention Research, 2010, 3, 114-124. Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the 94 1.6 National Health and Nutrition Examination Survey. Journal of Clinical Oncology, 2010, 28, 3951-3957.

#	Article	IF	CITATIONS
95	High-Density Lipoprotein Induces Proliferation and Migration of Human Prostate Androgen–Independent Cancer Cells by an ABCA1-Dependent Mechanism. Molecular Cancer Research, 2010, 8, 1284-1294.	3.4	63
96	Statin use is associated with improved prostate cancer survival: is it time for a clinical trial?. Expert Review of Anticancer Therapy, 2010, 10, 1563-1567.	2.4	9
97	Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19997-20002.	7.1	184
98	Statin use and cancer risk: a comprehensive review. Expert Opinion on Drug Safety, 2010, 9, 603-621.	2.4	235
99	The Association Between Statin Use and the Diagnosis of Prostate Cancer in a Population Based Cohort. Journal of Urology, 2010, 184, 494-500.	0.4	51
100	Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen. Journal of Urology, 2010, 183, 118-125.	0.4	42
101	2059 THE EFFECT OF DEMOGRAPHIC AND CLINICAL FACTORS ON THE RELATIONSHIP BETWEEN BMI AND PSA LEVELS. Journal of Urology, 2010, 183, .	0.4	0
102	Chemoprevention of Prostate Cancer. Urologic Clinics of North America, 2010, 37, 11-21.	1.8	16
103	Epilogue: Different approaches for prostate cancer screening in the EU?. European Journal of Cancer, 2010, 46, 3120-3125.	2.8	4
104	Effect of Statins on Serum Prostate-specific Antigen Levels. Urology, 2010, 76, 1048-1051.	1.0	17
105	Impact of HMG-CoA Reductase Inhibitor (Statin) Use on Blood Loss During Robot-Assisted and Open Radical Prostatectomy. Journal of Endourology, 2011, 25, 1427-1433.	2.1	2
106	Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement. Urologic Clinics of North America, 2011, 38, 325-331.	1.8	14
107	Association of Statin Use With Pathological Tumor Characteristics and Prostate Cancer Recurrence After Surgery. Journal of Urology, 2011, 185, 1268-1273.	0.4	46
108	The Complex Interplay Between Cholesterol and Prostate Malignancy. Urologic Clinics of North America, 2011, 38, 243-259.	1.8	61
109	Targeting liver X receptors in human health: deadlock or promising trail?. Expert Opinion on Therapeutic Targets, 2011, 15, 219-232.	3.4	73
110	The Metabolic Syndrome and Risk of Prostate Cancer in Italy. Annals of Epidemiology, 2011, 21, 835-841.	1.9	43
111	Cholesterol and benign prostate disease. Differentiation, 2011, 82, 244-252.	1.9	43
112	Statins and prostate cancer: Molecular and clinical aspects. European Journal of Cancer, 2011, 47, 819-830.	2.8	64

#	Article	IF	CITATIONS
113	Liver X receptors, lipids and their reproductive secrets in the male. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 974-981.	3.8	41
114	Re: Yang et al.: Lovastatin Causes Diminished PSA Secretion by Inhibiting AR Expression and Function in LNCaP Prostate Cancer Cells (Urology 2011;77:1508). Urology, 2011, 77, e3.	1.0	0
115	Screening for prostate cancer. European Journal of Cancer, 2011, 47, S164-S170.	2.8	25
116	Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer and Prostatic Diseases, 2011, 14, 340-345.	3.9	51
117	Statin Use and Risk of Prostate Cancer in a Population of Men Who Underwent Biopsy. Journal of Urology, 2011, 186, 86-90.	0.4	39
118	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer. Research and Reports in Urology, 0, Volume 3, 95-104.	1.0	0
119	Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells. International Journal of Oncology, 2011, 39, 561-8.	3.3	26
120	Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression. Journal of Thoracic Oncology, 2011, 6, 439-450.	1.1	61
121	Statins exhibit anticancer effects through modifications of the pAkt signaling pathway. International Journal of Oncology, 2011, 40, 867-75.	3.3	23
122	Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. Experimental and Therapeutic Medicine, 2011, 2, 221-228.	1.8	24
124	Effect of statin use on biochemical outcome following radical prostatectomy. BJU International, 2011, 108, E211-E216.	2.5	34
125	Perspective on prostate cancer screening. International Journal of Clinical Practice, 2011, 65, 31-34.	1.7	3
126	Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer and Prostatic Diseases, 2011, 14, 63-68.	3.9	27
127	Prostate cancer gene expression signature of patients with high body mass index. Prostate Cancer and Prostatic Diseases, 2011, 14, 22-29.	3.9	32
128	Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL. European Journal of Pharmacology, 2011, 673, 96-100.	3.5	36
129	Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity. Investigational New Drugs, 2011, 29, 883-890.	2.6	16
130	The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes and Control, 2011, 22, 417-426.	1.8	25
131	Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes and Control, 2011, 22, 1545-1552.	1.8	98

#	Article	IF	Citations
132	The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer, 2011, 11, 519.	2.6	12
133	The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate, 2011, 71, 1631-1637.	2.3	28
134	Statins increase the risk of prostate cancer: A populationâ€based case–control study. Prostate, 2011, 71, 1818-1824.	2.3	47
135	Improved Biochemical Outcomes With Statin Use in Patients With High-Risk Localized Prostate Cancer Treated With Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 713-718.	0.8	78
136	Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study. Cancer Epidemiology, 2011, 35, e6-e11.	1.9	11
137	Statins and Prostate Cancer Diagnosis and Grade in a Veterans Population. Journal of the National Cancer Institute, 2011, 103, 885-892.	6.3	90
138	Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort. Cancer Research, 2011, 71, 1763-1771.	0.9	188
139	Chinese Red Yeast Rice Inhibition of Prostate Tumor Growth in SCID Mice. Cancer Prevention Research, 2011, 4, 608-615.	1.5	24
140	A Novel Two-Stage, Transdisciplinary Study Identifies Digoxin as a Possible Drug for Prostate Cancer Treatment. Cancer Discovery, 2011, 1, 68-77.	9.4	145
141	Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of <i>LC3</i> transcription. Cancer Biology and Therapy, 2011, 12, 691-699.	3.4	67
142	Dyslipidemia, statins and prostate cancer. Expert Review of Anticancer Therapy, 2012, 12, 981-990.	2.4	9
143	Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study. British Journal of Cancer, 2012, 107, 207-214.	6.4	52
144	Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. Prostate Cancer and Prostatic Diseases, 2012, 15, 339-345.	3.9	25
146	Statin Use and Reduced Cancer-Related Mortality. New England Journal of Medicine, 2012, 367, 1792-1802.	27.0	798
147	Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths. Annals of Oncology, 2012, 23, 1325-1334.	1.2	90
148	Caveolin-1 and Prostate Cancer Progression. Advances in Experimental Medicine and Biology, 2012, 729, 95-110.	1.6	33
149	The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. Biochemical and Biophysical Research Communications, 2012, 425, 348-352.	2.1	9
151	Cholesterol and prostate cancer. Current Opinion in Pharmacology, 2012, 12, 751-759.	3.5	218

#	Article	IF	CITATIONS
152	Preoperative Statin Therapy is not Associated with Biochemical Recurrence After Radical Prostatectomy: Our Experience and Meta-Analysis. Journal of Urology, 2012, 188, 786-791.	0.4	27
153	Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. PLoS ONE, 2012, 7, e30062.	2.5	108
154	Diet, Obesity, and Prostate Health: Are We Missing the Link?. Journal of Andrology, 2012, 33, 763-776.	2.0	38
155	Should All Patients Receive Statins to Reduce Cancer Risk After Heart Transplantation?. Circulation, 2012, 126, 391-391.	1.6	1
156	Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48 <sup>Cre/+</sup> LSLâ€Kras <sup>G12D/+</sup> mice. International Journal of Cancer, 2012, 131, 1951-1962.	5.1	67
157	HMG CoA reductase inhibitors, NSAIDs and risk of glioma. International Journal of Cancer, 2012, 131, E1031-7.	5.1	46
158	The differential effects of statins on the metastatic behaviour of prostate cancer. British Journal of Cancer, 2012, 106, 1689-1696.	6.4	84
159	Statin use and fatal prostate cancer. Cancer, 2012, 118, 4046-4052.	4.1	54
160	Genetic variants associated with predisposition to prostate cancer and potential clinical implications. Journal of Internal Medicine, 2012, 271, 353-365.	6.0	80
161	Selective liver X receptor modulators (SLiMs): What use in human health?. Molecular and Cellular Endocrinology, 2012, 351, 129-141.	3.2	102
162	Increased nonâ€prostate cancer death risk in clinically diagnosed prostate cancer. BJU International, 2012, 110, 188-194.	2.5	2
163	Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene, 2013, 32, 961-967.	5.9	117
164	The Relationship Between Nutrition and Prostate Cancer: Is More Always Better?. European Urology, 2013, 63, 810-820.	1.9	80
165	Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncology, 2013, 49, 778-786.	1.5	44
166	Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1835, 219-229.	7.4	86
167	Exercise Therapy as Treatment for Cardiovascular and Oncologic Disease After a Diagnosis of Early-Stage Cancer. Seminars in Oncology, 2013, 40, 218-228.	2.2	38
168	Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. Journal of Clinical Oncology, 2013, 31, 3069-3075.	1.6	240
169	The Time Is Ripe for a Randomized Trial of Metformin in Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3054-3055.	1.6	15

#	Article	IF	CITATIONS
170	Re: Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. European Urology, 2013, 63, 178-179.	1.9	1
171	Simvastatin Induces Apoptosis in Castrate Resistant Prostate Cancer Cells by Deregulating Nuclear Factor-κB Pathway. Journal of Urology, 2013, 189, 1547-1552.	0.4	34
172	Simvastatin inhibits the core promoter of the TXNRD1 gene and lowers cellular TrxR activity in HepG2 cells. Biochemical and Biophysical Research Communications, 2013, 430, 90-94.	2.1	7
173	The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer. Vitamins and Hormones, 2013, 93, 51-98.	1.7	57
174	Statin Drugs and Prostate Cancer: Time to Consider Proactive Strategies in Patients. Journal of Urology, 2013, 189, 1192-1193.	0.4	1
175	Prostate Cancer and the Metabolic Syndrome. , 2013, , 107-114.		0
176	Association between Statin Usage and Prostate Cancer Prevention: A Refined Meta-Analysis Based on Literature from the Years 2005-2010. Urologia Internationalis, 2013, 90, 259-262.	1.3	15
177	Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of <i>ABCA1</i> . Cancer Research, 2013, 73, 1211-1218.	0.9	129
178	Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer. Anti-Cancer Drugs, 2013, 24, 1020-1029.	1.4	13
180	QSAR Model for Androgen Receptor Antagonism - Data from CHO Cell Reporter Gene Assays. Journal of Steroids & Hormonal Science, 2013, 01, .	0.1	2
181	A Prospective Study of Statin Drug Use and Lower Urinary Tract Symptoms in Older Men. American Journal of Epidemiology, 2013, 178, 797-803.	3.4	15
182	Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Annals of Oncology, 2013, 24, 1427-1434.	1.2	76
183	Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer and Prostatic Diseases, 2013, 16, 254-259.	3.9	53
184	Simvastatin Inhibits Proliferation and Induces Apoptosis in Human Lung Cancer Cells. Oncology Research, 2013, 20, 351-357.	1.5	51
185	C282Y-HFE Gene Variant Affects Cholesterol Metabolism in Human Neuroblastoma Cells. PLoS ONE, 2014, 9, e88724.	2.5	5
186	Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?. Prostate Cancer, 2014, 2014, 1-6.	0.6	26
187	The Diet as a Cause of Human Prostate Cancer. Cancer Treatment and Research, 2014, 159, 51-68.	0.5	38
188	Shared common variants in prostate cancer and blood lipids. International Journal of Epidemiology, 2014, 43, 1205-1214.	1.9	45

#	Article	IF	CITATIONS
189	Rho-GTPases and Statins: A Potential Target and a Potential Therapeutic Tool Against Tumors?. , 2014, , 209-245.		0
190	5α-Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1301.	5.1	38
191	Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer and Prostatic Diseases, 2014, 17, 6-9.	3.9	37
192	Re: Use of Statins and the Risk of Death in Patients with Prostate Cancer. European Urology, 2014, 65, 1219-1220.	1.9	Ο
193	The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. Journal of Urology, 2014, 191, 914-919.	0.4	39
194	Atypical plasma lipid profile in cancer patients: Cause or consequence?. Biochimie, 2014, 102, 9-18.	2.6	35
195	Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations. Journal of Genetic Counseling, 2014, 23, 187-191.	1.6	11
196	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. Cell Metabolism, 2014, 19, 393-406.	16.2	671
197	Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997–2010. Cancer Epidemiology, 2014, 38, 42-47.	1.9	45
198	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.	2.8	64
198 199	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982. Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.	2.8 1.6	64 616
198 199 200	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.         Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.         The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.	2.8 1.6 1.0	64 616 30
198 199 200 201	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.         Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.         The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.         Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.	2.8 1.6 1.0 2.8	64 616 30 53
198 199 200 201 202	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.	2.8 1.6 1.0 2.8 1.6	<ul> <li>64</li> <li>616</li> <li>30</li> <li>53</li> <li>126</li> </ul>
198 199 200 201 202 203	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer. British Journal of Cancer, 2014, 110, 2099-2108.	2.8 1.6 1.0 2.8 1.6 6.4	<ul> <li>64</li> <li>616</li> <li>30</li> <li>53</li> <li>126</li> <li>36</li> </ul>
198 199 200 201 202 203 203	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer. British Journal of Cancer, 2014, 110, 2099-2108.Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors inÂVivo. American Journal of Pathology, 2014, 184, 2099-2110.	2.8 1.6 1.0 2.8 1.6 6.4 3.8	<ul> <li>64</li> <li>616</li> <li>30</li> <li>53</li> <li>126</li> <li>36</li> <li>86</li> </ul>
<ul> <li>198</li> <li>199</li> <li>200</li> <li>201</li> <li>202</li> <li>203</li> <li>204</li> <li>205</li> </ul>	The failure of cancer chemoprevention. Carcinogenesis, 2014, 35, 974-982.Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 5-11.The strategies to control prostate cancer by chemoprevention approaches. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 760, 1-15.Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis, 2014, 35, 1547-1555.Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology, 2014, 32, 1-2.Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer. British Journal of Cancer, 2014, 110, 2099-2108.Hypercholesterolemia Induces Angiogenesis and Accelerates Crowth of Breast Tumors inÂVivo. American Journal of Pathology, 2014, 184, 2099-2110.Role of mitochondrial DNA changes in prostate cancer progression. Personalized Medicine Universe, 2014, 3, 57-58.	2.8 1.6 1.0 2.8 1.6 6.4 3.8 0.3	<ul> <li>64</li> <li>616</li> <li>30</li> <li>53</li> <li>53</li> <li>126</li> <li>36</li> <li>86</li> <li>0</li> </ul>

#	Article	IF	CITATIONS
207	Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1839-1850.	4.1	74
208	Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate, 2015, 75, 1384-1393.	2.3	25
209	A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer. Prostate, 2015, 75, 1916-1925.	2.3	23
210	Hyper-Lipidemia and Male Fertility: A Critical Review of Literature. , 2015, 04, .		10
211	Lovastatin enhances adenovirus-mediated TRAIL induced apoptosis by depleting cholesterol of lipid rafts and affecting CAR and death receptor expression of prostate cancer cells. Oncotarget, 2015, 6, 3055-3070.	1.8	20
212	Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean Journal of Urology, 2015, 56, 630.	1.2	17
213	Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Korean Journal of Urology, 2015, 56, 498.	1.2	0
214	The effect of statins on cancer cells—review. Tumor Biology, 2015, 36, 4889-4904.	1.8	105
215	Statin Use Reduces Prostate Cancer All-Cause Mortality. Medicine (United States), 2015, 94, e1644.	1.0	30
216	Statins are potential anticancerous agents (Review). Oncology Reports, 2015, 33, 1019-1039.	2.6	105
217	Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy, 2015, 14, 179-184.	0.5	12
218	Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. International Journal of Cancer, 2015, 137, 949-958.	5.1	17
219	The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostateâ€specific Antigenâ€era. International Journal of Cancer, 2015, 137, 2795-2802.	5.1	204
220	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	7.1	118
221	Statins are associated with a reduced risk of cholangiocarcinoma: a populationâ€based case–control study. British Journal of Clinical Pharmacology, 2015, 80, 755-761.	2.4	36
222	Postdiagnostic Statin Use and the Risk of Lethal Prostate Cancer in the Health Professionals Follow-up Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1638-1640.	2.5	12
223	Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate, 2015, 75, 211-217.	2.3	22
224	Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e11-21.e17.	1.6	25

#	Article	IF	CITATIONS
225	Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World Journal of Urology, 2015, 33, 93-97.	2.2	16
226	Lipid rafts as major platforms for signaling regulation in cancer. Advances in Biological Regulation, 2015, 57, 130-146.	2.3	251
227	Statin use and thyroid cancer: a populationâ€based case–control study. Clinical Endocrinology, 2015, 83, 111-116.	2.4	13
228	Hypercholesterolemia Is Associated with a Shorter Time to Castration-Resistant Prostate Cancer in Patients Who Have Undergone Androgen Deprivation Therapy. World Journal of Men?s Health, 2016, 34, 28.	3.3	7
229	Prostate Cancer: Is It a Battle Lost to Age?. Geriatrics (Switzerland), 2016, 1, 27.	1.7	11
230	Simvastatin blocks TGF-β1-induced epithelial-mesenchymal transition in human prostate cancer cells. Oncology Letters, 2016, 11, 3377-3383.	1.8	27
231	Statin Use and Prostate Cancer Aggressiveness: Results from the Population-Based North Carolina–Louisiana Prostate Cancer Project. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 670-677.	2.5	17
232	Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 547-554.	2.5	15
233	Cyp3a deficiency enhances androgen receptor activity and cholesterol synthesis in the mouse prostate. Journal of Steroid Biochemistry and Molecular Biology, 2016, 163, 121-128.	2.5	11
234	Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136.	2.8	68
235	LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. Scientific Reports, 2016, 6, 24521.	3.3	29
236	Statin Use in Prostate Cancer: An Update. Nutrition and Metabolic Insights, 2016, 9, NMI.S38362.	1.9	28
237	Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights, 2016, 9, LPI.S37450.	1.0	115
238	Association between preoperative serum total cholesterol level and biochemical recurrence in prostate cancer patients who underwent radical prostatectomy. Molecular and Clinical Oncology, 2016, 4, 1073-1077.	1.0	11
239	Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate International, 2016, 4, 56-60.	2.3	44
240	Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Research, 2016, 76, 4785-4790.	0.9	61
241	Epithelial cell migration as a potential therapeutic target in early lung cancer. European Respiratory Review, 2017, 26, 160069.	7.1	16
242	Combined effects of atorvastatin and aspirin on growth and apoptosis in human prostate cancer cells. Oncology Reports, 2017, 37, 953-960.	2.6	30

#	Article	IF	CITATIONS
243	Statin use and risk of multiple myeloma: An analysis from the cancer research network. International Journal of Cancer, 2017, 141, 480-487.	5.1	18
244	Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Prostate, 2017, 77, 446-457.	2.3	20
245	Atorvastatin attenuates testosteroneâ€induced benign prostatic hyperplasia in rats: role of peroxisome proliferatorâ€activated receptorâ€Î³ and cycloâ€oxygenaseâ€2. Fundamental and Clinical Pharmacology, 2017, 31, 652-662.	1.9	11
246	27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer. Chemistry and Physics of Lipids, 2017, 207, 108-126.	3.2	41
247	The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms. Chemico-Biological Interactions, 2017, 273, 273-285.	4.0	41
248	Epidemiology of Prostate Cancer. , 2017, , 107-125.		3
249	The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. Journal of Urology, 2017, 197, 1068-1075.	0.4	33
250	The current evidence on statin use and prostate cancer prevention: are we there yet?. Nature Reviews Urology, 2017, 14, 107-119.	3.8	111
251	Common medications and prostate cancer mortality: a review. World Journal of Urology, 2017, 35, 875-882.	2.2	15
252	Saturated fat intake and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana Prostate Cancer Project. Prostate Cancer and Prostatic Diseases, 2017, 20, 48-54.	3.9	32
253	Anticancer Agents in Combination with Statins. Journal of Bioequivalence & Bioavailability, 2017, 09, .	0.1	7
254	Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?. Journal of Clinical Oncology, 2017, 35, 3272-3274.	1.6	6
255	BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget, 2017, 8, 66051-66060.	1.8	14
256	Statin use linked with a decrease in the conversion from high-grade prostatic intraepithelial neoplasia (HGPIN) to prostate cancer. Carcinogenesis, 2018, 39, 819-825.	2.8	6
257	The effect of statin use on the incidence of prostate cancer: A populationâ€based nested case–control study. International Journal of Cancer, 2018, 143, 190-198.	5.1	12
258	The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030361.	6.2	461
259	Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030569.	6.2	48
260	Low-dose statin treatment increases prostate cancer aggressiveness. Oncotarget, 2018, 9, 1494-1504.	1.8	15

#	Article	IF	CITATIONS
261	Hybrid nanocarrier system for guiding and augmenting simvastatin cytotoxic activity against prostate cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 641-650.	2.8	19
262	Effects of statins on the chemoresistance—The antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine and Pharmacotherapy, 2018, 108, 1856-1865.	5.6	26
263	Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study. Cancer Prevention Research, 2018, 11, 779-788.	1.5	19
264	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. International Journal of Molecular Sciences, 2018, 19, 2545.	4.1	10
265	Statin Therapy to Improve Prostate Cancer Outcomes: Who, When, and for How Long?. European Urology, 2018, 74, 702-703.	1.9	2
266	The impact of transcription on metabolism in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R435-R452.	3.1	8
267	Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma. Cancer Letters, 2018, 431, 182-189.	7.2	16
268	Association of Statin Use With Overall and Cancer Survival. JAMA Oncology, 2018, 4, 1016.	7.1	1
269	The Heterogeneity of Lipid Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2018, 1063, 33-55.	1.6	60
270	Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 184-200.	1.6	83
271	Diet and Cancer. , 2018, , .		0
273	Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels. Cancers, 2019, 11, 953.	3.7	6
274	<p>Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells</p> . Cancer Management and Research, 2019, Volume 11, 7231-7242.	1.9	28
275	Statin use, hyperlipidemia, and risk of glioma. European Journal of Epidemiology, 2019, 34, 997-1011.	5.7	23
276	Anti-cancer effect of doxorubicin is mediated by downregulation of HMG-Co A reductase via inhibition of EGFR/Src pathway. Laboratory Investigation, 2019, 99, 1157-1172.	3.7	20
277	Oxidised lowâ€density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia. Andrologia, 2019, 51, e13321.	2.1	9
278	Cholesterol Induces Epithelial-to-Mesenchymal Transition of Prostate Cancer Cells by Suppressing Degradation of EGFR through APMAP. Cancer Research, 2019, 79, 3063-3075.	0.9	58
279	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Molecular Metabolism, 2019, 25, 119-130.	6.5	55

#	Article	IF	CITATIONS
280	Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. European Journal of Cancer, 2019, 112, 109-117.	2.8	53
281	Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. European Journal of Cancer, 2019, 112, 118-126.	2.8	36
282	Statin Use and the Risk of Prostate Cancer in Ischemic Heart Disease Patients in Taiwan. Clinical Pharmacology and Therapeutics, 2019, 106, 458-466.	4.7	10
283	Repurposed Drugs for Prostate Cancer. Cancer Journal (Sudbury, Mass ), 2019, 25, 121-126.	2.0	2
284	Use of vitamin K antagonists and risk of prostate cancer: Meta–analysis and nationwide case–control study. International Journal of Cancer, 2019, 144, 1522-1529.	5.1	7
285	Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study. Journal of Clinical Lipidology, 2019, 13, 148-155.	1.5	2
286	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	7.0	35
288	Statins as Anticancer Agents in the Era of Precision Medicine. Clinical Cancer Research, 2020, 26, 5791-5800.	7.0	103
289	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 630-637.	3.9	31
290	LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Seminars in Cancer Biology, 2021, 73, 134-157.	9.6	30
291	Lipid metabolism part I. , 2021, , 71-135.		0
292	Statins and Prostate Cancer: Bias, Precision Medicine, or Population Health?. European Urology, 2021, 79, 453-455.	1.9	1
293	Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial. EBioMedicine, 2021, 68, 103432.	6.1	12
294	A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-34.	4.0	4
295	Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone. Oncogene, 2021, 40, 4592-4603.	5.9	10
296	Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality. Scientific Reports, 2021, 11, 16171.	3.3	6
297	Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. Pharmaceutics, 2021, 13, 1509.	4.5	2
298	Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethnoâ€geographic variations. Prostate, 2021, 81, 1365-1373.	2.3	7

#	Article	IF	CITATIONS
299	The Heterogeneity of Lipid Metabolism in Cancer. Advances in Experimental Medicine and Biology, 2021, 1311, 39-56.	1.6	27
300	LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activatingÂthe STAT3 pathway. Journal of Cellular Physiology, 2021, 236, 5253-5264.	4.1	44
301	Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. PLoS ONE, 2012, 7, e46691.	2.5	177
302	Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21. PLoS ONE, 2013, 8, e70442.	2.5	60
303	Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. PLoS ONE, 2016, 11, e0161959.	2.5	15
304	MiR-33a and statins collaboratively reduce the proliferative capacity of prostate cancer cells. The European Research Journal, 0, , .	0.3	1
305	Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget, 2017, 8, 47110-47120.	1.8	24
306	Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget, 2011, 2, 1176-1190.	1.8	77
307	The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer. Current Drug Targets, 2019, 20, 738-747.	2.1	6
308	Clinical Potential of Statins in Prostate Cancer Radiation Therapy. , 2017, 37, 5363-5372.		19
309	Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian Journal of Urology, 2010, 26, 502.	0.6	19
310	Serum lipid profiles: novel biomarkers predicting advanced prostate cancer in patients receiving radical prostatectomy. Asian Journal of Andrology, 2015, 17, 239.	1.6	14
311	Terapia z wykorzystaniem statyn a stężenie testosteronu u mężczyzn. Endokrynologia Polska, 2015, 65, 464-468.	1.0	3
312	Significant Association of Metabolic Indices, Lipid Profile, and Androgen Levels with Prostate Cancer. Asian Pacific Journal of Cancer Prevention, 2014, 15, 9841-9846.	1.2	11
313	Association Between Statin Use and Risk for Keratinocyte Carcinoma in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Annals of Internal Medicine, 2009, 150, 9.	3.9	27
314	Lifestyle Changes, Nutritional Supplements, and General Preventive Medicine Recommendations That Can Simultaneously Improve Heart and Urologic Health: Part I. What Do I Tell Patients?. Seminars in Preventive and Alternative Medicine, 2007, 3, 74-87.	0.1	0
315	Statins, Diet, and Dietary Supplements for Prostate Cancer: A Potential Connection and Recommendation Based on Probability. Seminars in Preventive and Alternative Medicine, 2007, 3, 140-146.	0.1	0
316	Re: The influence of statins on prostate-specific antigen levels. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2009, 35, 93-94.	1.5	0

		CITATION REPORT		
#	Article		IF	CITATIONS
318	Efectos no hipolipemiantes de las estatinas. Acta Medica Costarricense, 2008, 49, .		0.1	1
319	Obesity, Type 2 Diabetes and Cancer. , 2012, , 37-72.			1
320	The Influence of Obesity on Prostate Cancer Diagnosis and Treatment. , 0, , .			0
321	Prostate Inflammation and Prostate Cancer. , 2012, , 103-115.			2
322	Staying a Step Ahead of Cancer. , 0, , .			0
323	The Role of Cholesterol in Prostate Cancer. , 2013, , 65-83.			0
324	Prevention and Early Detection of Urologic Cancers: A Mini-Review. , 2014, S, .			0
325	Prevention of prostate cancer. Zdravstvena Zastita, 2015, 44, 49-57.		0.2	0
326	Chemoprevention of Esophageal Cancer. , 2020, , 113-125.			0
327	Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospec Study. American Journal of Gastroenterology, 2022, 117, 158-166.	ctive Cohort	0.4	13
328	Statins Prevent Biochemical Recurrence of Prostate Cancer After Radical Prostatec Single-center Retrospective Study with a Median Follow-up of 51.20 Months. Rese in Urology, 2020, Volume 12, 439-446.	tomy: A earch and Reports	1.0	2
329	Metabolic imbalance and prostate cancer progression. International Journal of Molecul Epidemiology and Genetics, 2010, 1, 248-71.	ar	0.4	11
330	Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-b proteins. American Journal of Cancer Research, 2011, 1, 542-61.	inding	1.4	35
331	LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly. American Journa Research, 2013, 3, 58-69.	al of Cancer	1.4	10
333	Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate Access Journal of Urology, 2011, 3, 95-104.	cancer. Open	0.3	1
334	The evidence on trial: cholesterol lowering and cancer. Heart Asia, 2009, 1, 6-10.		1.1	0
335	Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination of Cancer. Cancer Genomics and Proteomics, 2016, 13, 151-60.	on Prostate	2.0	12
336	Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in Anticancer Research, 2014, 34, 3357-63.	vivo.	1.1	10

#	Article	IF	CITATIONS
337	Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy. American Journal of Translational Research (discontinued), 2020, 12, 5252-5268.	0.0	3
338	The association of statin use and biochemical recurrence after curative treatment for prostate cancer. Medicine (United States), 2022, 101, e28513.	1.0	7
339	Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review. World Journal of Men?s Health, 2022, 40, .	3.3	1
340	Cholesterol and saturated fatty acids synergistically promote the malignant progression of prostate cancer. Neoplasia, 2022, 24, 86-97.	5.3	22
341	Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Research, 2022, 24, 12.	5.0	12
342	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. Journal of Clinical Medicine, 2022, 11, 1313.	2.4	40
343	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	3
344	Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the ERK1/2 and COX-2 pathways. Translational Cancer Research, 2021, 11, 0-0.	1.0	0
345	Influence of statins in metastatic castration-resistant prostate cancer patients treated with new antiandrogen therapies: a systematic review and meta-analysis. Einstein (Sao Paulo, Brazil), 2022, 20, eRW6339.	0.7	2
346	Formulation of simvastatin within high density lipoprotein enables potent tumour radiosensitisation. Journal of Controlled Release, 2022, 346, 98-109.	9.9	8
349	Atorvastatin regulates the migration and invasion of prostate cancer through the epithelial-mesenchymal transformation and matrix metalloproteinase pathways. Investigative and Clinical Urology, 2022, 63, 350.	2.0	5
350	The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 999-1005.	2.5	0
351	Statin Use and the Risk of Prostate Cancer Biochemical Recurrence Following Definitive Therapy: A Systematic Review and Meta-Analysis of Cohort Studies. Frontiers in Oncology, 2022, 12, .	2.8	6
352	Effects of Lovastatin on Brain Cancer Cells. Cell Transplantation, 2022, 31, 096368972211029.	2.5	6
353	Statins and prostate cancer—hype or hope? The epidemiological perspective. Prostate Cancer and Prostatic Diseases, 2022, 25, 641-649.	3.9	14
354	Statins and prostate cancer—hype or hope? The biological perspective. Prostate Cancer and Prostatic Diseases, 2022, 25, 650-656.	3.9	7
355	Effect of Metabolic Syndrome in Patients with Prostate Cancer (Review). , 0, , .		0
356	The blockage of downstream P2Y2 receptor signaling inhibits the prostate cancer cell adhesion to endothelial cells. Life Sciences, 2022, 306, 120793.	4.3	3

#	Article	IF	CITATIONS
357	Statin Use Is Associated with Better Prognosis of Patients with Prostate Cancer after Definite Therapies: A Systematic Review and Meta-Analysis of Cohort Studies. Journal of Oncology, 2022, 2022, 1-10.	1.3	2
358	Long-Term Treatment with Simvastatin Leads to Reduced Migration Capacity of Prostate Cancer Cells. Biomedicines, 2023, 11, 29.	3.2	3
359	Association of Statin Use with the Risk of Incident Prostate Cancer: A Meta-Analysis and Systematic Review. Journal of Oncology, 2022, 2022, 1-13.	1.3	4
360	Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311528.	3.2	5
361	Statin therapy and sex hormones. , 2023, , 551-571.		0
362	Totalâ€, LDLâ€, and HDLâ€cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study. Prostate, 2023, 83, 1046-1059.	2.3	1
363	The effects of statins in patients with advanced-stage cancers -Âa systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	2.8	1
364	Metabolic pathway analysis using stable isotopes in patients with cancer. Nature Reviews Cancer, 2023, 23, 863-878.	28.4	6